Skip to main content

Day: April 21, 2025

Kraken Robotics Schedules 2024 Financial Results Release and Webcast

ST. JOHN’S, Newfoundland and Labrador, April 21, 2025 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces that it will release fiscal year 2024 financial results at 6:30am ET on Monday, April 28, 2025. The Company has also scheduled a webcast to discuss results on Monday, April 28, 2025 at 8:30am ET. The webcast will be hosted by Greg Reid, President and CEO and Joe Mackay, CFO of Kraken Robotics and will cover fourth quarter and full year 2024 results ending December 31, 2024. Webcast Details:Date: Monday, April 28, 2025 Time: 8:30am ET URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ktSbjyD1A recording of the webcast and supporting materials will be made available in the investor’s section of the Company’s website at https://www.krakenrobotics.com/investors.Figure...

Continue reading

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and...

Continue reading

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and...

Continue reading

Blue Moon Metals Appoints Boi Linh Doig as Vice-President, Mining

TORONTO, April 21, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce the appointment of Boi Linh Doig as Vice-President, Mining, as it continues to build out its management team to support the Company’s continued growth in the development of its three polymetallic brownfield projects. “We are delighted to welcome Boi Linh to our team,” said Christian Kargl-Simard, CEO of Blue Moon. “With her solid experience in underground mining within the challenging Red Lake Gold Camp over the last 20 years, she brings extensive expertise in both operational leadership and strategic mine planning and will be pivotal in the advancement of all three underground development projects.” Mrs. Doig has over 20 years of underground experience in the mining industry....

Continue reading

Castellum, Inc. Reduces Principal Balance by $2 Million on Notes Payable to Robert Eisiminger and Extends Maturity Date

Castellum, Inc. Reduces Principal Balance by $2 Million on Notes PayableCastellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”) entered into an amendment to a letter agreement to, among other things, reduce the principal balance on two notes payable to Robert Eisiminger by $2 Million, leaving an aggregate principal balance owed of $4 million – https://castellumus.com/VIENNA, Va., April 21, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that it has entered into an amendment to a letter agreement to, among other things, reduce the principal balance on two notes payable to Robert Eisiminger by $2 Million, leaving an aggregate principal...

Continue reading

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10%BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled “The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.” “Chronic low back pain is...

Continue reading

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks’ clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023, will continue as Executive Vice President & Chief Medical Officer, with primary responsibility for Zymeworks’ emerging R&D portfolio...

Continue reading

Jeffs’ Brands: Fort Submits Android Version of AI-Based Pest Control App to Google Play

Tel Aviv, Israel, April 21, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that its wholly-owned subsidiary, Fort Products Limited (“Fort”), has submitted the Android version of its artificial intelligence (AI)-powered pest control mobile application for review on Google Play. This follows the successful completion of the development and internal testing of the mobile app, marking a major milestone as Fort transitions from internal validation towards commercial rollout.  The application harnesses AI to help users identify pests and recommends tailored treatments based on species, infestation severity, and user preferences. It also features curated product suggestions, including Fort’s...

Continue reading

Niu Technologies to Report First Quarter 2025 Financial Results on May 19, 2025

BEIJING, April 21, 2025 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the first quarter 2025 before the U.S. market opens on Monday, May 19, 2025. The corporate presentation and financial spreadsheets will be posted on NIU’s investor relations website at:https://ir.niu.com/financial-information/quarterly-results The Company will host an earnings conference call on Monday, May 19, 2025 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time) to discuss the financial and business results. To join via phone, participants need to register in advance of the conference call using the link provided below. Upon registration, participants will receive dial-in numbers and a personal...

Continue reading

Change to Financial Calendar: New Publication Date for Annual Report.

April 21st, 2025        Change to Financial Calendar: New Publication Date for Annual Report. Roskilde, 21st April – Photocat A/S announces a revision to its financial calendar regarding the publication of the Annual Report for the financial year 2024. Previously, the financial calendar indicated a publication date of 23 April 2025. This date was published in error and had not been confirmed with the company’s auditors. The Annual Report will instead be published on 6 May 2025, which is in accordance with the company’s Articles of Association and consistent with previous years’ reporting timelines. We regret any inconvenience this may have caused and appreciate the understanding of our shareholders and stakeholders. For more information, please contact:Michael HumlePhotocat A/STel: +45 7022 5055Email: ka@photocat.net About Photocat:Photocat...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.